Ayush-64 Technology Transferred To 46 Companies For COVID Treatment

New Delhi: The technology of Ayush-64 has been transferred to 46 companies by the Central Council for Research in Ayurvedic Sciences (CCRAS).

Ayush 64 drug is used in mild and asymptomatic and mild to moderate cases of COVID-19.

CCRAS, the premier research institution in Ayurveda under the Ministry of AYUSH, has developed the Ayush-64 drug. It was developed in 1980 for treating malaria.

Some scientific studies found the drug effective for mild and asymptomatic and mild to moderate cases of COVID-19 during the first wave in March 2020.

The drug contains properties of fighting viruses, increases immunity in patients and reduces fever helping patients recover quickly.

Earlier, only seven companies, which included the manufacturing unit of the Ayush Ministry, had the licence for the drug. But after it was found effective during the COVID-19 outbreak, the government gave fresh licences to 39 new companies and transferred the technology to them.

ALSO READ: COVID Vaccine Booster: Pfizer, Moderna Shots Cleared For All US Adults